Posted on

Wesana Health Closes $4 Million Convertible Note Round

Funding to support Company’s entrance into the psychedelics space

New additions to senior management and leadership teams

CHICAGO, Jan. 21, 2021 /PRNewswire/ — Wesana Health, an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, has announced the close of a $4 million convertible note financing round. The company also announced new additions to its senior leadership team.

Wesana Health Raises Funds to Enter the Psychedelics Space

The $4 million round, led by The Conscious Fund and Ambria Capital, LLC, provides funding to support the Company’s entry into the emerging psychedelics space. The proceeds will allow Wesana to begin preclinical and clinical work on the use of psychedelic-assisted therapy to treat traumatic brain injury (TBI) as well as regulatory applications including Investigational New Drug (IND) filings with the Food and Drug Administration (FDA), and Investigational Medicinal Product Dossier (IMPD) filings with Health Canada. In addition, the funds will support the build out of Wesana’s staffing and senior leadership teams.

“Partners such as The Conscious Fund and Ambria Capital, two of the leading venture investment firms in the psychedelic space, validate the Wesana business model as we enter into the next phase of our mission to improve the quality of life and overall well-being of those suffering from traumatic brain injury,” said Daniel Carcillo, Co-Founder and CEO of Wesana Health. “As someone who has personally suffered from the debilitating repercussions of repeated trauma to the brain, I know firsthand that mental healthcare in our society is greatly lacking due to poor treatment options. Our focus is on removing the stigma that exists around neurological disorders and advancing psychedelic-based therapies that will allow people to retake control of their health and overcome their trauma.”

Daniel Carcillo is a former professional hockey player who won two Stanley Cup Championships with the Chicago Blackhawks before being forced to retire at the age of 30 due to post-concussion syndrome. In the years following his professional hockey career, Carcillo has been steadfastly focused on researching and developing natural-sourced neurological treatment regimens to treat TBI. Daniel is a leading advocate for the emerging psychedelics space and sits on the board of the Heroic Hearts Project, a registered 501(c)(3) non-profit that connects military veterans struggling with mental trauma to psychedelic therapy options including ayahuasca, psilocybin and ketamine.

“As one of the leading early-stage psychedelic medicine venture funds, we were impressed by Daniel’s evolution from advocate for TBI sufferers, to creating an elite team with Chad, going from speaking out to solving real world challenges,” said Henri Sant-Cassia, Founding Partner of The Conscious Fund.

“Passionate people are at the heart of every successful medical effort, and we are pleased to continue to support the dedicated teams behind them,” said Cody Shandraw, Director for Ambria Capital, LLC. “Based upon Daniel’s tireless advocacy work, the company’s clinical development plan, and continued growth of their patent portfolio, we feel that Wesana is positioning itself for success in the future. We are confident that our investment will help capitalize on opportunities as they arise and accelerate the execution of their overall business plan.”

New Additions to Senior Management and Leadership Teams

Wesana Health announced several new members of the Company’s senior leadership and management teams with the additions of Chad Bronstein as Executive Chairman of the Board; Dawn McCollough as Chief Operating Officer; Ian McCall as Director of Athlete Relations; as well as the appointment of Mitch Kahn to the Company’s Board of Directors.

Mr. Bronstein, a Co-Founder of Wesana Health, has been appointed to serve as Executive Chairman of the Board of Directors. In addition to his duties at Wesana, Mr. Bronstein currently serves as CEO of Fyllo, a leading technology company he founded in 2019 that provides media and compliance solutions to highly regulated industries. Mr. Bronstein has more than a decade of operating, capital raising and public markets expertise and, in his role as Executive Chairman, will leverage his extensive entrepreneurial experience to support the Company’s development and future growth.

Ms. McCollough joins Wesana Health as Chief Operating Officer with over 26 years of experience overseeing global clinical development activities including the approval of drugs and multiple flu and pandemic vaccines. Prior to joining Wesana Health, Ms. McCollough served as head of Medical Research Operations and Research Team in Late-Stage Development at Biogen. Ms. McCollough also previously served as Head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics.

Mr. McCall is a retired American mixed martial arts World Champion, CBD ambassador, psychedelic research and psilocybin advocate as well as coach and mentor. In his role as Director of Athlete Relations, McCall will work closely alongside Carcillo to recruit and enroll athletes suffering from TBI, and who have not been healed by traditional treatments for their conditions, in a series of psychedelic-assisted therapy clinical trials. In addition, McCall will serve as an ambassador for the Company leveraging his acute knowledge and relationships within the athlete community to educate his peers on the promise of psychedelic and mycelia-based medicines. Since his retirement in 2018, McCall has become one of the most prominent voices advocating for the safe use of psilocybin and plant medicines to treat professional sports injuries and drug dependence.

Mr. Kahn was the Founder and CEO of the largest private, vertically integrated cannabis operation in the United States, Grassroots Cannabis, which was recently purchased by Curaleaf Holdings. As CEO of Grassroots, Kahn led over 1100 employees across 11 states and obtained more than 60 regulatory licenses in the emerging cannabis sector. Kahn also serves as Co-Founder and Chairman of Frontline Real Estate Partners, a Chicago-based real estate investment and advisory company with expertise in the acquisition, development, management, disposition and leasing of commercial real estate properties throughout the United States with a focus on the Midwest. In addition to his role at Grassroots and board position with Wesana Health, Mr. Kahn also sits on the Board of Directors at Fyllo and Curaleaf.

“I’m thrilled to announce the newest additions to our leadership team as we push forward with a laser focus on delivering an innovative psychedelic-therapy program that will enhance how we treat traumatic brain injuries,” added Carcillo. “Leveraging the expertise of Chad, Dawn, Mitch and Ian, we are now in a position to pursue transformational opportunities and create therapies that will result in better outcomes for those suffering from various forms of mental illness.”

About Wesana Health
Wesana Health is an emerging life sciences company championing the development and delivery of psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI). Through extensive clinical research and academic partnerships, Wesana Health is developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological and mental health ailments caused by trauma.

Learn more at www.wesanahealth.com

Cision View original content:http://www.prnewswire.com/news-releases/wesana-health-closes-4-million-convertible-note-round-301212481.html

SOURCE Wesana Health

Released January 21, 2021

Posted on

BETTER PLANT AFFILIATE NEONMIND LISTS ON THE FRANKFURT STOCK EXCHANGE (FSE: 6UF)

Vancouver, B.C. – January 19, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF“. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE.  Shares of Better Plant are available on the FSE under the symbol “YG3”.

The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its participants. Of the approximately 200 market participants, roughly 50% are from countries other than Germany.

The FSE facilitates advanced electronic trading, settlement and information systems, allowing it to meet the growing requirements of cross-border trading.

 

About NeonMind Biosciences Inc.

NeonMind is a preclinical psychedelic drug development company. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia. NeonMind has filed five U.S. provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogues or by administering psilocybin or its analogue in conjunction with therapy or other treatments.  NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four mushroom-infused coffees containing medicinal mushrooms Lion’s Mane, Turkey Tail, Reishi and Cordyceps which are available for purchase online in Canada at www.neonmind.com.

For more information on NeonMind, go to www.NeonMindbiosciences.com or buy NeonMind mushroom infused coffee at www.NeonMind.com.

 

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 29.2% of NeonMind.

 

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

 

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

 

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

New Wave Holdings subsidiary, Way of Will Inc. is pleased to announce its launch of high-quality mushroom products for Q1 2021

TORONTO, Jan. 14, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XM2) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to announce its launch of high quality new functional mushroom wellness collection under Way of Will Inc.

New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)
New Wave Holdings Logo (CNW Group/New Wave Holdings Corp.)

WAY OF WILL Joins the ‘Shroom Boom’ with High Quality Functional Mushroom Wellness Collection

Known and loved for their wellness formulas that incorporate natural plant-based ingredients, WAY OF WILL is pleased to announce an upcoming launch of a new product line featuring one of nature’s best ingredients: mushrooms. As part of a recent acquisition by New Wave, one of the primary goals is to make WAY OF WILL a more well-rounded and holistic company, beginning with the integration of functional mushrooms into the existing health and wellness product line.

This exciting new Functional Mushroom Collection will contain products that can be categorized into five different health and wellness subcategories. This includes:

  • An Antioxidant Blend for better overall skin heath
  • An Immunity Blend that promotes overall immunity health
  • A Brain Function Blend to help combat stress and increase brain function
  • An Energy Blend that gives a mental and mood boost
  • An Adaptogen Blend that promotes sleep and relaxation

Some of the functional mushroom varieties that can be found in the new products include Lion’s Mane, Reishi, Cordyceps, and Chaga. Each ingredient in the functional mushroom blends is carefully selected for their powerful and nutritional benefits, as well as their effectiveness in providing a natural way to maintain one’s health and wellness. WAY OF WILL has been working closely with experts and pioneers in the field to formulate new products based on the five functions in the collection.

While WAY OF WILL’s current array of aromatherapy products already focuses on benefits highlighted in the five categories listed above, the new collection will allow the trusted brand to offer a broader selection of natural wellness products to consumers.

“Our culture at WAY OF WILL is to create the highest quality plant-based nutraceuticals in the aromatherapy space,” said Willie Tsang, founder and CEO. “After countless months of hard work, we are excited to soon be able to offer new products to customers that utilize an assortment of functional mushrooms, which has been a well-loved ingredient in skincare and wellness.”

The development of this product line came after conducting extensive email surveys on current and projected market demands. Since then, multiple key chain buyers have already expressed interest in this new collection.

The products in this new line will be manufactured with our U.S. and Canadian partners. It is anticipated that the collection will leverage WAY OF WILL’s ecommerce expertise along with established relationships with wholesale partners and manufacturing partners.

This is the beginning of WAY OF WILL’S journey into the expansion of the functional mushroom product category. The Mushroom Collection is expected to launch mid-March this year.

ABOUT NEW WAVE HOLDINGS CORP.

New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTCPK: TRMNF) is an investment issuer focused on the burgeoning psychedelic sector and support for adaptive and progressive mental health products and therapies. In the psychedelic sector, New Wave will focus on supporting research on active psychedelic compounds, creation of consumer products based on functional mushrooms, and developing an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases. New Wave also contains various health and beauty products within its portfolio of non-psychoactive plants and fungi as it continues to expand its product distribution through vertical integration to provide end to end solutions while capturing a high margin business model.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com

Information relating to WAY OF WILL INC., contained in this news release was provided by WAY OF WILL INC. and/or its agent and has not been independently verified by the Company. The Company does not take responsibility for the accuracy of such information.

The CSE has not in any way passed on the merits of the Acquisition, and neither has approved nor disapproved the contents of this press release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Certain statements contained in this news release may constitute forward–looking information, including but not limited to, applicable regulatory approval in connection with the Acquisition, the closing of the Acquisition, expansion of operations, size and quality of future tournaments and projections regarding attendance at future events. Forward–looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company’s actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company’s strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-holdings-subsidiary-way-of-will-inc-is-pleased-to-announce-its-launch-of-high-quality-mushroom-products-for-q1-2021-301208519.html

SOURCE New Wave Holdings Corp.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/14/c3086.html

Posted on

Technology Networks

Substance use disorders have a debilitating impact on the wellbeing of individuals and their families. Like many other mental health disorders, these conditions have proved stubbornly resistant to treatment. The potential of psychedelic compounds to treat substance use disorders has led Canadian R&D company Entheon Biomedical to investigate the therapeutic use of the psychedelic dimethyltryptamine (DMT). The company has commissioned a clinical trial investigating the safety and efficacy of intravenous DMT. Technology Networks spoke to Entheon’s CEO, Timothy Ko, to find out more.

Ruairi Mackenzie (RM): What will be involved in the first stage of your DMT clinical trial?

Timothy Ko (TK): We have a clinical study agreement in place with a contract research organization, the Centre for Human Drug Research (CHDR) located in Leiden, Netherlands, to conduct an early phase clinical trial with DMT on humans. The objective of the study is to evaluate the safety of DMT in humans and, specifically, we’re looking to better understand the pharmacodynamics and pharmacokinetics of DMT when administered intravenously.

This will be a data-centric clinical trial, gathering vital information on the biochemical and physiological changes that occur when DMT is administered. This trial will give us further insight into the drug’s effects on the central nervous system and its impact on subjective experience, providing not only pharmacokinetic/pharmacodynamic but also a host of other valuable biometric data. All of this is critical to properly understand DMT’s potential as part of a therapeutic protocol to treat substance use disorders.

RM: What do you see as the unique challenges in treating substance abuse disorders in comparison to other mental health disorders?

TK: The success rates of current treatments and interventions are dismal, and as a society, we have become conditioned to accept these low rates of success as a foregone conclusion. We want to turn those assumptions upside down – to invert the addiction-recovery ratio and we believe we can do it through the development of a DMT-based therapeutic protocol.

Substance-use disorder is obviously a very complicated situation for both the individual grappling with it and for a society and public health system that is tasked with addressing and remedying the devastating effects and widespread damage that stems from unchecked substance-use disorder. With no straightforward solution present, our belief is that a medicalized, psychedelic-assisted therapy model provide a powerful tool for substance-use sufferers to gain the clarity and support required to reclaim their lives.

RM: How is DMT well placed to meet those challenges?

TK: Through extensive talks with our scientific advisors, a review of the literature and historical studies, DMT emerged as our ideal candidate for addiction treatment. DMT belongs to a class of psychedelic compounds, including psilocybin and LSD, which have shown high therapeutic value, and it is the psychoactive ingredient in ayahuasca. Being endogenous to the human body, DMT can be found in many plant species, and throughout its research history DMT has demonstrated a strong safety and toxicology profile. In addition, DMT is rapidly metabolized, so it is well-suited for a shorter, more tailored therapy experience, which has the added benefit of decreased costs and increased scalability. The ability to maintain a flexible and short therapy duration provides an element of control that cannot presently be achieved with other longer-lasting psychedelics. DMT is short-acting, powerful and has demonstrated safety in humans. These are the core reasons why we chose to focus our efforts on DMT.

RM: Do you believe that DMT will prove efficacious for all substance use disorders, or will it treat certain disorders more effectively?

TK: Our initial target indications will be nicotine addiction, alcohol-dependency and opioid use disorder. That being said, our DMT-assisted therapeutic protocol is being designed to address the core mechanisms underlying drug-seeking and using behaviour. Understanding that these drug-seeking behaviours are generated from a complex psychological and emotional place, DMT holds promise to directly address this base state, from which all manner of substance-use disorders are thought to originate from. From this standpoint, our aim is to prove efficacy for the initial target indication and then expand to focus on additional indications and substance-use disorders.

RM: What is the timeline for your DMT trial? How soon do you believe psychedelic-based therapeutics could be widely available?

TK: Recognizing the potential constraints of the ongoing coronavirus pandemic, we currently anticipate that our clinical trial at CHDR will commence in Q3 of 2021. We are doing everything we need logistically to ensure our trial remains on track.

Recently we announced our DMT drug-supply agreement with Psygen Labs, and that they have successfully completed production of our DMT research batch. This represents a major step in our clinical pathway, as the commencement of clinical trials and preparation hinges on having a consistent and high-quality drug supply. Once all necessary permits and licenses are in place, our drug-supply will be shipped to CHDR for requisite testing and formulation.

We are proving the safety and efficacy of our treatment protocol through standard regulatory channels that traditional drug developers go through – the FDA, EMA, and Health Canada. We expect that given our current trajectory, we would like to be in the final stages of clinical development and ready to seek final approvals and pursue commercialization in 4-5 years. But really, given the pressing need for effective treatments, paired with the growing loss of life from overdose, and the significant social and economic impact of substance-use disorders, an effective and scientifically validated solution cannot come quickly enough.

Timothy Ko was speaking to Ruairi J Mackenzie, Science Writer for Technology Networks

Posted on

BETTER PLANT AFFILIATE NEONMIND TO COMPLETE FULLY SUBSCRIBED IPO AND COMMENCE TRADING ON MONDAY, JANUARY 4, 2021 UNDER THE SYMBOL NEON

Vancouver, B.C. –  December 29, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) announces the common shares of its partially owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) are now approved for trading on the Canadian Securities Exchange (the “Exchange”) as a new listing under the stock ticker symbol “NEON”.  NeonMind expects to close its fully subscribed Initial Public Offering on December 30, 2020 and commence trading on the Exchange under the symbol “NEON” on Monday, January 4, 2021.

The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”.   Better Plant owns 33,313,500 common shares in NeonMind, which are  subject to an escrow agreement which releases the shares for transfer in tranches over a 3 year period, in accordance with National Policy 46-201.

More information on NeonMind and the NeonMind IPO can be found in NeonMind’s final prospectus which is available on SEDAR at www.sedar.com under issuer information for NeonMind Biosciences Inc.

 

About NeonMind Biosciences Inc.

NeonMind plans to help people change their lives by changing their minds, through treatment with psychedelics.  It is tackling one of the biggest health issues the world is facing right now: obesity. It’s an epidemic that is responsible for 37% of the global burden of disease, according to the World Health Organization. NeonMind is engaged in research to develop a patent pending treatment using psilocybin (a complex organic compound found in psychedelic mushrooms) to cause weight loss. It commenced a Preclinical Trial in November 2020 at the University of British Columbia after Health Canada granted authorization to the Principal Investigator to use psilocybin for NeonMind’s Preclinical Trial.

NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity,  and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments.

NeonMind has also commercialized a collection of 4 coffees infused with medicinal mushrooms Lion’s Mane, Turkey Tail, Reishi and Cordyceps, which are available for purchase in Canada at www.neonmind.com.

 

About Better Plant Sciences Inc. 

Better Plant offers a collection of high-efficacy, plant-based products for optimum health and wellness. It creates formulations with the highest quality, natural raw ingredients, combining modern science with nature to create highly-effective, results-driven products for the mind, body and home.

It is a vertically-integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products.  Better Plant is committed to staying at the forefront of plant-science research and development, and is constantly engaged in research to further expand its portfolio of over 400 proprietary formulations and over 70 SKUs which are currently for sale. Its all natural formulas are designed for health optimization, all without chemicals or harmful ingredients.  Better Plant also supports and develops companies with products or services that can help create a better planet, with healthier and happier people.  Its minority owned subsidiary NeonMind Biosciences is  developing treatments with psychedelics and has commercialized  a line of plant-based coffees infused with health optimizing medicinal mushrooms which are for sale at www.neonmind.com.  Better Plant operates the direct to consumer platforms www.getjusu.com and www.urbanjuve.com.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Director of Investor Relations

invest@betterplantsciences.com 

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the closing of the NeonMind IPO, the listing of NeonMind on the Exchange, risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

TORONTO, Dec. 23, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.

The Company’s clinical safety team has actively monitored the ongoing interim data of patients and found there have been no safety concerns and no severe adverse events during the interim analysis enrollment period. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, there have been no serious safety concerns that required the DSMB to be notified.

There are currently nine clinical sites participating in the Study with an additional six more clinical sites joining the Study in January to satisfy the overall enrollment goal of up to 1,000 patients.

Further to the DSMB review and recommendations on the interim analysis periods, the Company aims to file for an Emergency Use Authorization (“EUA”) of Bucillamine for mild to moderate COVID-19 with the FDA. In November 2020, the FDA also issued an EUA to permit the emergency use of bamlanivimab (manufacturer Eli Lilly) and the combination of casirivimab and imdevimab (manufacturer Regeneron) for the treatment of mild to moderate COVID-19.

A recently published study, titled “Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry” from the University of California San Francisco, shows that thiol-based drugs, like Bucillamine, decrease the binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. The findings uncovered a vulnerability of SARS-CoV-2 to thiol-based drugs and provide rationale to test thiol-based drugs as novel treatments for COVID-19. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than N-acetyl-cysteine. Bucillamine has a well-known safety profile with over 30 years of use as a treatment for rheumatoid arthritis in Japan and South Korea.

“We are pleased with the progress we have made to date in our Phase 3 clinical trial with the potential for Bucillamine to become the first orally administered drug to obtain emergency use access from the FDA and also potentially providing another therapeutic option for healthcare professionals to use in treating mild to moderate COVID-19,” said Michael Frank, CEO of Revive.

About the Phase 3 Clinical Trial (ClinicalTrials.gov Identifier: NCT04504734)

The Phase 3 confirmatory clinical trial titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of the first dose through Day 28 following randomization. Efficacy will be assessed by comparing clinical outcomes (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation.

An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for 28 days after randomization. The DSMB is independent from the Company, the investigators of the Study, or anyone involved in the clinical care of the Study subjects and oversees the safety of participating patients by reviewing the Study’s accumulating safety and efficacy data for Bucillamine. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports.

Scientific Rationale of Bucillamine for COVID-19

Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.3 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.4-7 In addition, it was found that thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection.8 Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2020, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

References

1. H Ibrahim et al, Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine., Clinical Immunology. Volume 219, October 2020, 108544.

2. LD Horwitz, Bucillamine: a potent thiol donor with multiple clinical applications, Cardiovasc Drug Rev. 2003 Summer;21(2):77-90).

3. S Ye et al, Inhibition of Reactive Oxygen Species Production Ameliorates Inflammation Induced by Influenza A Viruses via Upregulation of SOCS1 and SOCS3., American Society for Microbiology. 2015 Mar;89(5):2672-2683).

4. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. 1997 Jul;10(7):1535-41).

5. M Mata et al, N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)., Biochem Pharmacol. 2011 Sep;82(5):548-55.

6. D Ungheri et al, Protective effect of n-acetylcysteine in a model of influenza infection in mice., Int J Immunopathol Pharmacol. 2000 Sep-Dec;13(3):123-128.

7. RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. 2014 Sep;22(1):1-8).

8. K Khanna, et al, Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies., bioRxiv. 2020 Dec 8.

Posted on

New Medical Cannabis Patient Center Opens in Blaine, Minnesota

VIEW ALL NEWS

Posted on

BETTER PLANT AFFILIATE NEONMIND ANNOUNCES FILING OF FINAL PROSPECTUS IN CONNECTION WITH AN INITIAL PUBLIC OFFERING

Vancouver, B.C. – December 10, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) announces that on December 9, 2020 its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind“) obtained a receipt for a final prospectus for an initial public offering (the “NeonMind IPO”) for the sale of up to 46,000,000 units at $0.10 per unit (the “Units”) to generate gross proceeds of up to $4,600,000, in conjunction with a conditional approval for listing on the Canadian Securities Exchange (the “Exchange”). The Units are being offered for sale to the public in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario through NeonMind’s agent, Mackie Research Capital Corporation.

 

No securities in Better Plant are being sold as part of the NeonMind IPO offering. The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”.

 

The NeonMind IPO is subject to a minimum subscription of 20,000,000 Units (the “Minimum Subscription Amount”). The Exchange granted NeonMind conditional approval to its common shares for trading on the Exchange, subject to a number of conditions, including raising the Minimum Subscription Amount. Each Unit will consist of one common share in the capital of NeonMind (a “NeonMind Share”) and one share purchase warrant to purchase one additional NeonMind Share of NeonMind at a price of $0.20 per share for a period of 12 months from the closing of the NeonMind IPO. Upon the successful completion of the NeonMind IPO and subject to regulatory approval, it is anticipated that NeonMind Shares will be listed for trading on the Exchange under the stock symbol “NEON”. Better Plant currently owns 33,313,500 NeonMind Shares out of 66,430,500 NeonMind Shares currently issued and outstanding. Better Plant also owns 55,000,0000 warrants (the “NeonMind Warrants”) to purchase NeonMind Shares at $0.20 per share until May 6, 2022. The NeonMind Shares and NeonMind Warrants owned by Better Plant are subject to an escrow agreement whereby the securities will be released in tranches over a 35 month period, beginning 30 days after the date NeonMind’s common shares begin to trade on the Exchange. Currently, Better Plant owns approximately 50.1% of the outstanding and issued NeonMind Shares. Under the NeonMind IPO, up to an additional 46,000,000 NeonMind Shares could be issued, assuming the over-allotment option is exercised, resulting in up to 112,430,500 NeonMind Shares issued and outstanding, which could reduce Better Plant’s ownership percentage in NeonMind to as low as 29.6%. There is no guarantee that NeonMind will achieve the Minimum Subscription Amount required to complete the NeonMind IPO.

 

NeonMind is developing products that contain legal medicinal mushrooms and it is engaged in preclinical research into potentially therapeutic uses of compounds found in psychedelic mushrooms. NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments. NeonMind’s long-term goal is to develop one or more products that incorporate restricted psychedelic substances to treat illness, with its product candidate being developed to treat obesity and promote or cause weight loss.

 

More information on NeonMind and the NeonMind IPO can be found in NeonMind’s final prospectus which is available on SEDAR at www.sedar.com under issuer information for NeonMind Biosciences Inc.

 

No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale or any acceptance of an offer to buy these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities under the IPO have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly, in the United States or to, or for the account of benefit of, U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or solicitation of an offer to buy any of these securities in any jurisdiction in which the offering or sale is not permitted.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 75 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 51% of NeonMind.

 

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram. Buy Jusu plant-based home and body products at getjusu.com and buy plant-based Urban Juve skin care products at urbanjuve.com.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Director of Investor Relations

invest@betterplantsciences.com

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Psychedelics: FDI’s next trip?

By Seth O’Farrell

Published at FDIIntelligence.com

‍

Psilocybin-based therapies are gaining ground in the US, sparking investment in the sector

The past few months has seen a flurry of activity to do with psychedelics in North America: US cities and states have legalised psilocybin, and biotech psychedelic-assisted therapy companies have started to raise institutional capital and establish R&D centres overseas.

In November, the state of Oregon decriminalised the possession of all drugs and legalised the use of psilocybin – the naturally occurring compound found in “magic mushrooms” – for medical treatment. This comes as biotech companies developing psilocybin therapy, such as Compass Pathways, look to raise capital funding through IPOs.

On both sides of the Atlantic, guided therapy using psilocybin as a conduit is gaining ground, while investor interest is surging. Psychedelics stocks are fast becoming a hot topic in the biotech sector.

The business potential is not lost on investors. In 2017, the UK’s Centre for Mental Health estimated that mental health problems at work had cost the country £34.6bn, up from £26bn 10 years earlier. Global predictions for the financial cost of mental health run to trillions. With Covid-19 exacerbating the rates of anxiety, depression and addiction, it is little wonder that capital is coming to the rescue.

Indeed, it follows that companies large and small are expanding their operations. Greenfield investment tracker fDi Markets recorded two projects in this sector this year. Despite concurrent legalisation efforts, how companies court investors and acquire regulatory approval remains delicate, however.

Canadian company Mydecine, which develops and produces drugs from mushrooms, has opened a lab in Denver focused on the medical applications of mushrooms of non-psychedelics and is awaiting DEA approval.

“We think that the US is an amazing marketplace,” says Mydecine chief executive Josh Bartch, adding that the decriminalisation in Oregon and lobbying efforts in Washington DC have led to a “wave of acceptance” and “mindset changes”.

Covid-19 fallout

In the wake of the pandemic and the second lockdown restrictions across Europe and North America, concerns around mental health and wellbeing are only likely to become more pronounced.

Mr Bartch expects a surge in post-traumatic stress disorder and a spike in substance abuse, for which psilocybin is a unique treatment. “People will be actively seeking out more progressive, innovative and less harmful solutions,” he says.

For J.R. Rahn, CEO and founder of MindMed, a Toronto-based psychedelic medicine biotech company, being federally compliant and distancing oneself from the legalisation path are essential to attracting institutional capital.

He fears that legalisation efforts may ignore the needs of the patients who are suffering, and so priority must be given to the patients before any debate on legalisation.

“Right now, let’s solve the acute problem that tens of millions of Americans are jobless and are probably going to have high rates of mental illness and addiction,” Mr Rahn says. “The whole legalisation thing has the ability to threaten what we’re doing in the therapeutic space.Our objective is not for you to have a better Phish concert. Our objective is to solve the underlying cause of your anxiety or addiction.”

MindMed opened a research and development centre in Basel earlier this year, attracted by the research going on in Switzerland and the infrastructure that is already in place to conduct clinical trials there.

“There is a huge Swiss legacy on psychedelics,” he says, which goes all the way back to Basel-born chemist Albert Hofmann’s discovery of LSD.

Humanitarian opportunity

It is hard not to make comparisons with the evolution of the cannabis industry over the past 10 years, whereby legal changes have aligned with public acceptance to create a billion-dollar medical industry. Legalisation efforts in the US have removed much of the stigma attached to alternative, psychoactive medicine, and the country’s opioid crisis led to greater openness regarding plant-based alternatives.

Ronan Levy, co-founder and executive chairman of Canadian psychedelic therapeutics company Field Trip Health, which recently expanded operations to the Netherlands, insists that this is distinct from the popularisation of cannabis-inspired medicine in both mission and scope.

“The cannabis industry was driven more through political grassroots activism,” he says. The difference here is that this surge of interest has been triggered by the research coming out of Baltimore’s Johns Hopkins University and Imperial College, London.

“This is not only an incredible business opportunity but an incredible humanitarian opportunity,” Mr Levy asserts. “Research shows that people who have psychedelic therapies have increased creativity and empathy.”

In a divided world, he adds, humanity is evolving in a positive way as the psychedelics industry begins to flourish.

Posted on

HAVN LIFE ATTRACTS INTERNATIONAL DRUG SCIENCE AND POLICY EXPERT, JOINS UK POLICY REFORM GROUP

Havn Life has joined the UK-based Conservative Drug Policy Reform Group (CDPRG), a group organized to benefit drug policy-making

The Havn Life Advisory Board adds Mr. King, a vocal advocate for drug policy reform and research.

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG).

The Company is also pleased to announce that David King, director of research for CDPRG, has joined the Havn Life advisory board. King has co-authored several CDPRG white papers including ‘The UK Review of Medicinal Cannabis: The Needs of a Nation’ and ‘The Medicinal Use of Psilocybin: A call for reform.’ This year, King received the Dr Abbas Khan Medal by King’s College London for ‘outstanding humanitarian contributions to the service of society’.

He is also a founder of the Breaking Convention, Europe’s largest academic conference on psychedelic drug research, and was a founding director of the Breaking Convention charity from 2010 to 2019.

The CDPRG is a UK-based organization that assembles evidence from across the fields of medicine, law-enforcement, economics, ethics, criminology and human rights, for the benefit of drug policy-making. This year the CDPRG launched a campaign to reschedule psilocybin in the UK as part of their mission to provide greater access for research and medicinal purposes. Havn Life will commission 250 hours of work from CDPRG’s researchers.

“Being a part of the CDPRG global network of scientists allows us to utilize multidisciplinary expertise to develop psilocybin protocols that can have global impact,” says Tim Moore, Havn Life CEO. “Collaboration across fields allows us to move the needle. We are building a strong foundation of knowledge to develop a safe and reliable supply of naturally-derived psychedelic compounds for research”.

“As the clinical trial evidence for psychedelic therapies grows, it becomes increasingly clear that these interventions are safe, well-tolerated, and have the potential to change lives for the better, sometimes after only a single session,” says King. “We do not yet know what the real-world impact of these therapies will be, but there are good reasons to believe that we will be better equipped to treat some of the most difficult and burdensome conditions of the modern age, for which new approaches are desperately needed.”

King completed his undergraduate degree in medical anthropology in 2011, with a research thesis on beliefs and attitudes to health, illness and medicine among cannabis-using populations. He has also worked as a researcher at the Beckley Foundation and in immunology at the National University of Singapore.  King was the founding President of both the award-winning Psychedelics Society at the University of Kent and the Society for Psychedelic Studies at King’s College London.

King first met Havn Life Chief Psychedelic Officer Dr. Ivan Casselman when they both were students together at the School of Anthropology and Conservation, University of Kent, over ten years ago.

“I am delighted to be working with Dr. Casselman and the other members of the Havn Life team as they move from strength to strength,” King adds. “Their collective experience, acumen and energy is remarkable and I anticipate the group accomplishing a great deal in the years ahead.”

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096